Hologic Continues Spending Spree With $230M Tuck-In Acquisition Of Biotheranostics
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.
You may also be interested in...
Following the purchase of Mobidiag, Hologic has aggressively launched the Novodiag platform across Europe in a bid to dominate the local molecular diagnostics market.
Mobidiag develops molecular diagnostic tests and instrumentation that will expand Hologic’s acute care testing capabilities.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.